JANX in the 13F filings
Janux Therapeutics Inc · CUSIP 47103J105
- Quarter end
- 31 Dec 2025
- the date the book describes
- Filed
- 19 Feb 2026
- latest of these filings; the earliest 10 Feb 2026
- Managers listing it
- 27
- at least, of 95 tracked, among listed positions
- Comparable managers
- 92
- filed both Q3 2025 and Q4 2025; 3 listed it in both
- Shares listed
- 18,011,581
- combined, among listed positions
- Reported value
- $249m
- combined, at the quarter end
Among the 92 comparable managers: 21 buyers (opened or added shares) and 6 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was -2,058,587.
Managers listing JANX in Q4 2025
27 of 27 holders
Largest increases and reductions, by shares
Increases
- Wellington Management Group LLPexisting position · 1,610,186 shares now+908,582
- Balyasny Asset Management LLCnew position · 885,551 shares now+885,551
- Janus Henderson Group Ltdexisting position · 5,350,453 shares now+649,341
- Jane Street Group LLCexisting position · 540,233 shares now+458,911
- Two Sigma Investments LPexisting position · 471,009 shares now+367,533
Reductions
- Fidelity (FMR LLC)existing position · 3,512,384 shares now-5,543,678
- Point72 Asset Management LPexisting position · 961,819 shares now-748,381
- T. Rowe Price Associates Incexisting position · 744,466 shares now-521,090
- Susquehanna International Group LLPexisting position · 35,237 shares now-133,904
- Tudor Investment Corpexisting position · 79,158 shares now-19,398
New positions and exits
New (10)
Exited (1)
- Verition Fund Management LLCwas $995k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2021 | 1 | $8.3m | n.a. | n.a. |
| Q3 2021 | 1 | $6.5m | n.a. | n.a. |
| Q4 2021 | 1 | $5.5m | n.a. | n.a. |
| Q1 2022 | 1 | $4.0m | n.a. | n.a. |
| Q2 2022 | 1 | $3.5m | n.a. | n.a. |
| Q3 2022 | 1 | $5.4m | n.a. | n.a. |
| Q4 2022 | 1 | $6.7m | n.a. | n.a. |
| Q1 2023 | 1 | $1.7m | n.a. | n.a. |
| Q2 2023 | 1 | $1.6m | n.a. | n.a. |
| Q3 2023 | 1 | $864k | n.a. | n.a. |
| Q1 2024 | 3 | $76m | 3 | 0 |
| Q2 2024 | 3 | $98m | 2 | 2 |
| Q3 2024 | 5 | $218m | 4 | 1 |
| Q4 2024 | 8 | $850m | 6 | 1 |
| Q1 2025 | 3 | $174m | 1 | 2 |
| Q2 2025 | 4 | $182m | 1 | 2 |
| Q3 2025 | 3 | $182m | 1 | 3 |
| Q4 2025 | 2 | $88m | 21 | 6 |
| Q1 2026 | 1 | $58m | 10 | 14 |
| Q2 2026 | 1 | $1.4m | 14 | 13 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
JANX and LLY →JANX and JNJ →JANX and VRTX →Choose a stock to compare with JANX →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own JANX, latest filings →Back to the 13F Explorer →